World Preview 2026: A $2tn Industry at a Glance

Global prescription drug sales will exceed $2 trillion by 2032.

Tirzepatide is on course to become the biggest-selling drug in history, cardiovascular and immunology are reshaping the therapy area rankings, and the patent cliff is pushing M&A firmly back onto the agenda. This infographic pulls the headline numbers from Evaluate’s World Preview 2026 for a quick view of the years ahead.

Share:

Download today








The infographic covers the top-selling drugs and companies in 2032, the therapy areas growing fastest, and the dealmaking picture for companies most exposed to loss of exclusivity.

The infographic covers:

• Which drugs will top the sales rankings in 2032, and what that means for the competitive landscape
• The top 10 pharma companies by projected 2032 revenue, and who is growing fastest
• Which therapy areas are driving growth – and which are losing ground
• The companies most exposed to patent expiry through 2032, and how they are responding

Upcoming Webinar

World Preview 2026

Tuesday 16th June 2026 | 3pm BST

By 2032, the global pharmaceutical market is forecast to reach almost $1.9tn. Inside the innovations, dealmaking, and portfolio strategies transforming the global biopharma pipeline.

Frequently Asked Questions

The World Preview 2026 infographic is a one-page visual summary of the key findings from Evaluate’s annual World Preview report. It covers global prescription drug sales forecasts to 2032, the top-selling drugs and companies, therapy area growth rates, patent expiry exposure and the strategic questions shaping the biopharma industry’s outlook.

Evaluate forecasts worldwide prescription drug sales will exceed $2 trillion by 2032, up from $1.3 trillion in 2026, representing a compound annual growth rate of 7.1%. Growth is led by drugs for obesity and inflammatory conditions.

Tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, is forecast to be the biggest-selling drug in history by 2032, with projected annual sales of $45.5 billion.

Eli Lilly is forecast to be the top-selling pharma company in 2032 with projected prescription drug sales of $137.1 billion, growing at a CAGR of 12.3% from 2026.

AbbVie, AstraZeneca and Merck face the greatest exposure from loss of exclusivity through 2032, with up to $500 billion in combined sales at risk.

Related Content